Skip to Main Content
  • Linde Worldwide
  • The Linde Group
  • About Linde
  • Careers
  • Glossary
  • Healthcare
    Sri Lanka

  • Home
  • About COL Healthcare
      • Mission
      • Healthcare professionals
      • Patient-focused care
      • Innovation
        • Innovation in healthcare
        • Your partner
        • REALfund
      • Locations
  • Products and Services
      • Products and Services by category
        • Medical gases
        • Hospital equipment
        • QI Medical Gas Services
      • Products and Services by disease area
        • Anaesthesia
        • Intensive care
        • Obstetrics
        • Pain
        • Pulmonology
      • Products and Services by care area
        • Emergency care
        • Hospital and clinical care
  • News & Media
      • Sri Lanka News
      • Global News
      • Events
        • Events Archive
      • Publications
      • Media Contacts
  • Careers
      • Jobs @ Linde
  •  
  • Linde Worldwide
  • The Linde Group
  • About Linde
  • Careers
  • Glossary
  • News & Media
  • Sri Lanka News
  • Global News
  • Events
  • Publications
  • Media Contacts
  • News & Media
  • Global News
  • 2012-07-09 Linde AG approves capital increase

Linde AG approves capital increase Ad-hoc-announcement according to section 15 WpHG

Adhoc News

Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan.

Munich, 9 July 2012 - With the approval of the Supervisory Board the Executive Board of Linde AG approved a capital increase from authorised capital against cash contribution of up to EUR 33,280,000.00 by issuing up to 13,000,000 new no-par-value bearer shares with exclusion of subscription rights of the shareholders.

The new shares will be offered to institutional investors within an international private placement by way of an accelerated bookbuilding. A public offer will not take place.

The capital increase is one element of the funding of the intended acquisition of Lincare Holdings Inc. by Linde AG. The total consideration of the acquisition will be USD 4.6 bn.

The issue price is expected to be set and published on 10th July 2012.


This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, or the United States of America (the “United States”) or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.

The tender offer described herein has not yet commenced, and this material is neither an offer to purchase nor a solicitation of an offer to sell shares of Lincare Holdings Inc. common stock. At the time the tender offer is commenced, Linde will file a tender offer statement with the United States Securities and Exchange Commission (the “SEC”). Lincare Holdings Inc.  shareholders are strongly advised to read the tender offer documents that will be filed with the SEC because they will contain important information that Lincare Holdings Inc. shareholders should consider before tendering their shares. These documents will be available for free at the SEC’s website (http://www.sec.gov) and by directing a request to Linde AG, Klosterhofstraße 1, 80331 Munich, Germany.

Linde Aktiengesellschaft
Klosterhofstr. 1
80331 Munich
www.linde.com
info@linde.com

ISIN:  DE0006483001

 

For further information:

Media
Uwe Wolfinger 
Phone +49.89.35757-1320
Investor Relations
Dr Dominik Heger
Phone +49.89.35757-1334
Matthias Dachwald
Phone +49.89.35757-1333
Lisa Tilmann
Phone +49.89.35757-1328

    • Terms of Use
    • Legal Notice
    • Data Protection
  • © Ceylon Oxygen Limited 2019

To enhance your user experience and to deliver our online services, this website uses cookies for reasons of functionality, comfort and statistics. By continuing to browse the site, you are agreeing to our use of cookies.
You can find out more on our data protection information.
You must check the "I accept cookies from Linde Sites" box to accept.
More